Future directions in lung cancer research and therapeutics.
Although immune and genetic approaches do not yet have substantial clinical exposure in NSCLC, it is hoped that the future will bring less toxic, more specific, and more effective methods to prevent the development of end-stage NSCLC. The principles of multitargeted and multimodality therapy to overcome tumor heterogeneity and resistance, and drug delivery issues have been developed over years of effort using chemotherapy. The lessons learned should not be forgotten, because they will remain applicable to newer biologic and genetic modalities.
Elias
A D
AD
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000517:prevention & control / Q000628:therapy*; D015316:Genetic Therapy; D006801:Humans; D007167:Immunotherapy; D008175:Lung Neoplasms / Q000175:diagnosis / Q000517:prevention & control / Q000628:therapy*
D000970:Antineoplastic Agents